Report Overview

The US Antiplatelet and Antithrombotic Drug market was valued at nearly USD 136 million in 2019 and is projected to grow at a CAGR of XX% from 2019 to 2028

Thrombosis is a condition when the blood clot is formed called a thrombus. Thrombus prevents the blood flow in blood vessels and may cause the death of cells and serious medical conditions. Antithrombotic drugs are used to prevent or treat thrombus formation. The growing number of chronic diseases that lead to thrombosis coupled with the increase in the geriatric population is expected to drive the market growth. Furthermore, the presence of strong drug pipelines such as Tecarfarin, TB-402, and others and their expected commercialization is projected to boost the market growth over the coming years. However, stringent regulatory policies and the high cost of novel drugs are expected to hamper the market growth



Market Growth Drivers

The increasing prevalence of cardiac and cancer diseases is one of the factors which is expected to drive the overall anti-platelet and anti-thrombotic drugs. The significant growth in a market over a forecast period is mainly attributed due to hereditary diseases. Increasing awareness about life-threatening diseases among people is a key factor that might fuel the sales of the overall anti-platelet and anti-thrombotic drug market. The unavailability of alternatives for antithrombotic drugs coupled with the new product developments and launches are expected to bolster the market growth. Changing lifestyles and lack of physical activity is one of the factors which affects the growth of the market moderately during the forecast period. Failure to take antiplatelet drugs as prescribed can possess an increased risk of thrombotic complications, owing to rebound platelet activation. All these factors are expected to hinder the growth of the antiplatelet drug market during the forecast period